ZFN was the first genome editing tool used in a clinical trial [NCT03432364; ST-400-01, Sangamo Therapeutics, and Sanofi] for the BCL11A erythroid enhancer disruption in thalassemic and SCD- patient-derived CD34+cells. The gene discussed is CD34; the disease is Schnyder corneal dystrophy.